SSG
DRNA

Summit Securities Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Summit Securities Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5,263
Closed -$67K – 771
2014
Q3 		$67K Buy
+5,263
New +$79.4K 0.02% 357

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summit Securities Group's DRNA Position: Q4 2014 in Review

Summit Securities Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2014, closing a stake of 5,263 shares — an estimated $67K sold.

Summit Securities Group first reported a position in DRNA in Q3 2014 and held it in 1 quarter. The position peaked at $67K in Q3 2014. 47 funds tracked by Wall St. Rank hold DRNA as of Q4 2014.

  • Summit Securities Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Summit Securities Group sold 5,263 Dicerna Pharmaceuticals, Inc. shares in Q4 2014, an estimated $67K.
  • Summit Securities Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2014 and held it in 1 quarter.
  • Summit Securities Group's Dicerna Pharmaceuticals, Inc. position peaked at $67K in Q3 2014.
  • 47 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2014.

Based on Summit Securities Group's 13F filing for Q4 2014, filed 5 Feb 2015.